Stada and Xbrane Biopharma have struck a co-development deal covering the Swedish firm’s Xlucane (ranibizumab) biosimilar, a proposed rival to Genentech’s Lucentis, with a worldwide scope.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?